FDA Approves First Transdermal Patch for Schizophrenia
The US Food and Drug Administration (FDA) has approved a transdermal patch formulation of asenapine (Secuado) as the first patch for the treatment of adults with schizophrenia, Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., announced. The once-daily patch provides sustained concentrations of the atypical antipsychotic asenapine during its […]
Read More